Solid Biosciences Reports Strong Interim Results for SGT-003 Gene Therapy in Duchenne Trial

Solid Biosciences’ gene therapy SGT-003 shows early promise for Duchenne; trial patients improved muscle and heart function, with potential accelerated FDA approval in 2026.